Renal injury in the extremely obese patients with normal renal function  by Serra, A. et al.
see commentary on page 909
Renal injury in the extremely obese patients with
normal renal function
A Serra1, R Romero1, D Lopez2, M Navarro1, A Esteve3, N Perez4, A Alastrue4 and A Ariza2
1Departments of Nephrology and Medicine, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Badalona,
Barcelona, Spain; 2Department of Pathology, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona,
Badalona, Barcelona, Spain; 3Department of CEESCAT, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona,
Badalona, Barcelona, Spain and 4Department of General Surgery, Hospital Universitari Germans Trias i Pujol, Autonomous University of
Barcelona, Badalona, Barcelona, Spain
We studied the glomerular architecture in renal biopsies of
95 patients undergoing bariatric surgery for extreme obesity
but whose renal function was normal. The comparison group
was 40 control patients having protocol biopsies. These latter
patients had normal weight and renal function, were non-
diabetic, non-hypertensive, and were undergoing
nephrectomy or donating a kidney. Logistic regression
models determined associations between the clinical and
biochemical variables and glomerular lesions. Arterial
hypertension, sleep apnea syndrome (SAS), and
microalbuminuria were prevalent in the obese patients, as
was hyperglycemia to a lesser extent. Focal and segmental
glomerulosclerosis was present in only five extremely obese
(EO) patients but absent in controls. Increased mesangial
matrix, podocyte hypertrophy, mesangial cell proliferation,
and glomerulomegaly were more frequent in the obese
cohort than in the control group. Body mass index was a
significant independent risk factor associated with
glomerular lesions in all 135 patients and in the 95 EO
patients, whereas SAS was associated with glomerulomegaly
only in the EO. Our study shows that EO patients who lack
overt clinical renal symptoms have a variety of glomerular
abnormalities that correlate with body mass.
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Obesity and extreme obesity are health problems of epidemic
proportions imparting an increased risk for conditions as
common as type 2 diabetes mellitus, arterial hypertension,
and cardiovascular diseases.1 However, excess weight has not
been widely considered to be a major cause of kidney disease.
In 1974, Weisinger et al.2 described the association between
extreme obesity and focal and segmental glomerulosclerosis
(FSGS) in two patients with nephrotic-range proteinuria.
One year later, Cohen3 reported the presence of glomer-
ulomegaly in autopsies of five extremely obese (EO) patients.
Later, works concerning renal lesions in obesity have been
limited to case reports,4–7 studies of small numbers of
patients,8,9 or autopsy series10,11 of patients with overt renal
manifestations. Additionally, a retrospective clinicopatholo-
gic study by Kambham et al.12 including 71 obese patients
with proteinuria or chronic renal failure has been recently
published. FSGS and glomerulomegaly were the most
common renal lesions found in that review. Thus, histo-
logical studies of renal injury in extreme obesity have been so
far limited to patients with overt renal manifestations.
The importance of obesity as one of the main risk factors
for kidney disease has recently been accepted, especially when
considering that hypertension and type 2 diabetes mellitus
(both closely related to obesity) are the leading causes of end-
stage renal disease.13 Furthermore, obesity could also be an
independent risk factor for chronic kidney disease. Recent
epidemiological data suggest the existence of this relation-
ship.14–16 However, very little is known on the overall
prevalence of biopsy-proven renal lesions in extreme
obesity.17,18
Given that available data regarding renal histological
lesions in patients with extreme obesity are limited (those
that do exist were obtained from patients with proteinuria or
chronic renal failure), the main aim of this study was to
analyze whether patients without clinical renal involvement
show obesity-related renal structural changes. We also
investigated whether there are any clinical or biochemical
variables that, together with obesity, could be responsible for
the renal lesions observed. This topic is extremely important
owing to the worldwide epidemic increase in obesity.
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2008 International Society of Nephrology
Received 12 July 2007; revised 5 November 2007; accepted 20
November 2007; published online 23 January 2008
Correspondence: R Romero, Department of Nephrology, Hospital Uni-
versitari Germans Trias i Pujol, Universitat Auto`noma de Barcelona, Carretera
de Canyet s/n, Badalona 08916, Spain.
E-mail: rromero.germanstrias@gencat.net
Kidney International (2008) 73, 947–955 947
RESULTS
Our study population comprised 95 EO patients19 (body
mass index (BMI)X40 kg m2) who underwent renal biopsy
during bariatric surgery. Clinical, biochemical, and patho-
logical data from these patients were compared with those
from 40 control subjects.
Baseline clinical and biochemical data
Mean age of the 95 EO patients (36 men, 59 women) was
41.8±10.1 years (range: 19–59), mean BMI 53.6±9.2 kg m2
(range: 40–94 ), and mean obesity duration time 236±105
months. Fifty-six (59%) EO patients showed arterial hyper-
tension, 44 (46%) sleep apnea syndrome (SAS), 13 (14%)
fasting serum glucose between 7 and 11 mmol l1, 36
impaired fasting serum glucose, 38 hypercholesterolemia,
and 28 hypertriglyceridemia. All patients showed normal
serum creatinine levels. Creatinine clearance was above
140 ml min1 in 31 patients and between 90 and 140 ml min1
in the remainder. Thirty-nine patients (41%) had micro-
albuminuria and 4 (4%) albuminuria 4300 and o500 mg
per 24 h. Forty-eight EO patients were smokers.
Mean age of the 40 control subjects (23 men, 17 women)
was 42.0±12.9 years (range: 18–59) and their mean BMI
23.9±2.4 kg m2 (range: 19–27). All controls showed normal
plasma creatinine and negative proteinuria. None showed
diabetes mellitus or arterial hypertension. Four control
subjects showed impaired fasting serum glucose, six
hypercholesterolemia, and three hypertriglyceridemia. Eleven
were smokers.
When clinical and biochemical variables were compared
between EO patients and controls, only weight, BMI, systolic
blood pressure, fasting glucose, and 24-h proteinuria showed
statistically significant differences (Table 1).
Baseline renal histological data
Light microscopy. EO patients (5 (5.3%)) showed FSGS (classic
or usual FSGS (Figure 1a) in three cases and perihilar FSGS in
two cases). FSGS was not observed in control renal biopsies.
The percentage of globally sclerosed glomeruli was higher in
patients than in controls (P¼ 0.007). Increased mesangial
matrix (Po0.001) (Figure 1b), mesangial cell proliferation
(P¼ 0.005), and podocyte hypertrophy (Figure 1c)
(Po0.001) were found in a higher percentage in EO patients
than in controls. Seventy-three percent of EO patients and 5%
of controls showed increased mesangial matrix and/or
mesangial cell proliferation and/or podocyte hypertrophy
(Po0.001). Glomerular area was significantly greater in EO
patients than in controls (Po0.001). Glomerulomegaly
(Figure 1d) was observed in 38% of EO patients and 2.5%
of controls (Po0.001), this being the sole glomerular lesion in
six EO patients. Of the five EO patients with FSGS, one
showed glomerulomegaly and four suffered from SAS. Seven
(54%) diabetic EO patients revealed increased mesangial
matrix and five showed (38%) glomerulomegaly. Glomer-
ulomegaly was seen in 51% of EO patients with SAS and in
28% of EO patients without SAS (P¼ 0.038). No differences
were found in relation to tubulointerstitial or vascular lesions
between patients and controls. Table 2 summarizes the
number of patients and the score of tubulointerstitial and
vascular lesions. All five patients with FSGS showed interstitial
fibrosis ((1þ ) in 4 cases and (2þ ) in 1 case) and arteriolar
lesions ((2þ ) in all cases).
Immunofluorescence studies were available in 69 EO
patients and were positive in six of them: (3þ ) granular and
diffuse mesangial IgA deposition in one case; (3þ ) granular,
focal and segmental mesangial IgM, and C3 deposition in one
case; (1þ ) granular and diffuse mesangial IgM deposition in
one case; and (1þ ) linear IgG deposition in the glomerular
capillary wall in three cases. Only one of the latter three
patients showed serum fasting plasma glucose 47 mmol l1.
Electron microscopy was available in 23 EO patients
without FSGS. The main finding shown by nonsclerosed
glomerular capillaries was the presence of large-sized
podocytes with swollen cytoplasms that occasionally revealed
Table 1 | Clinical and biochemical parameters in 95 EO patients and 40 normal-weight controls
Patients Controls P-value
Gender (women) 59 (62.1%) 17 (42.5%) NSa
Age (years)b 41.8±10.1 42.0±12.9 NSc
Body weight (kg)b 149.4±25.7 67.4±9.3 o0.001c
BMI (kg m2)d 52 (46.9–58.3) 24.6 (22.1–26.0) o0.001e
BMI (kg m2) of patients with FSGSd 58.7 (50.6–63) 24.6 (22.1–26.0) o0.001e
Systolic blood pressure (mm Hg)d 138 (130–150) 130 (120–137) o0.001e
Diastolic blood pressure (mm Hg)d 81 (70–90) 80 (70–85) NSe
Serum fasting glucose (mmol l1)d 5.2 (4.9–6.5) 5.1 (4.7–5.5) 0.017e
Serum total cholesterol (mmol l1)b 4.9±1.0 4.6±1.1 NSc
Serum triglycerides (mmol l1)d 1.3 (1.2–1.7) 1.2 (0.9–1.6) NSe
Plasma proteins (g l1)b 69±5.6 67±7.0 NSc
Serum creatinine (mmol l1)b 78.3±11.4 79.2±16.7 NSc
24-h proteinuria (g per 24 h)d 0.14 (0.10–0.34) 0.10 (0.10–0.12) 0.012e
BMI, body mass index; EO, extremely obese; FSGS, focal and segmental glomerulosclerosis; NS, nonsignificant.
aPearson’s w2 test with continuity correction.
bMean±s.d.
cStudent’s t-test.
dMedian values and interquartile ranges.
eMann–Whitney U-test.
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lipid reabsorption (Figure 1e). Evidence of podocyte fusion
was mild (approximately 10% of the glomerular capillary
surface area). In addition, mat-like condensations of
cytoskeletal filaments parallel to the glomerular basement
membrane were observed (Figure 1f).
Association between clinical, biochemical, and renal
pathological data in extremely obese patients
The presence of FSGS was found to be significantly associated
with a higher percentage of globally sclerosed glomeruli
(P¼ 0.007) and interstitial fibrosis (P¼ 0.031), but not with
glomerulomegaly (P¼ 0.356) or SAS (P¼ 0.112). The
association between FSGS and arteriolosclerosis was close
to statistical significance (P¼ 0.060). EO patients with FSGS
did not show BMI greater than EO patients without FSGS,
but did exhibit higher degrees of 24-h albuminuria (108
(69–219) mg vs 17 (9–72) mg per 24 h) (P¼ 0.019). Diabetic
EO patients did not show more FSGS lesions, mesangial
sclerosis, glomerulomegaly, or 24-h albuminuria than non-
diabetic EO patients. EO patients with SAS did not show
statistically significant differences with regard to the presence
of FSGS lesions, higher creatinine clearance, or 24-h
albuminuria than those without SAS.
Glomerulomegaly was significantly associated with in-
creased mesangial matrix (P¼ 0.005) and SAS (P¼ 0.045)
(Figure 2), but not with a higher percentage of globally
sclerosed glomeruli, mesangial hypercellularity, podocyte
hypertrophy, higher creatinine clearance, or higher 24-h
albuminuria. EO patients with podocyte hypertrophy, greater
percentage of globally sclerosed glomeruli, interstitial fibrosis,
a b
c d
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Figure 1 | (a) Focal and segmental glomerulosclerosis. Two peripheral sclerotic lesions showing focal adhesion to Bowman’s capsule (Masson
trichrome stain, original magnification  400). (b) Global mesangial matrix increase in both glomeruli (Masson trichrome stain, original
magnification  200). (c) Hypertrophic podocytes that contain intracytoplasmic droplets of fat resorption (arrow) and prominent nucleoli
(arrow) (H&E stain, original magnification  1000). (d) Glomerulus with glomerulomegaly from an extremely obese patient and glomerulus
without glomerulomegaly from a control of the same age (H&E stain, original magnification  400). (e) Electron microscopy. Large-sized
podocyte with intracytoplasmic lipids and focal foot process fusion (uranyl acetate and lead citrate stain, original magnification  4000). (f)
Mild fusion of podocytes and condensations of cytoskeletal filaments with a parallel orientation to the glomerular basement membrane (uranyl
acetate and lead citrate stain, original magnification  10 000).
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and tubular atrophy did not show higher levels of 24-h
albuminuria than patients without these lesions.
Risk factors for glomerular lesions
Extremely obese patients and controls. Univariate and
multivariate logistic regression models were performed in
EO patients and controls to ascertain which clinical and
biochemical variables were associated with glomerular lesions
(increased mesangial matrix and/or mesangial cell prolifera-
tion and/or podocyte hypertrophy) (Table 3). A significant
univariate association was found among these glomerular
lesions and BMI and systolic and diastolic blood pressure.
However, only BMI significance remained in the multivariate
model. When 13 EO patients with plasma fasting glucose
levelsX7 mmol l1 were excluded, we found that BMI (odds
ratio (OR)¼ 2.14; 95% confidence interval (CI): 1.56–2.93)
was also statistically associated with glomerular lesions.
Additionally, when logistic regression analysis was performed
to ascertain risk factors associated with the presence of
sclerosed glomeruli, we found that age (OR: 1.58; 95% CI:
1.07–2.34) and BMI (OR: 1.20; 95% CI 1.03–1.39) were
independent risk factors in the multivariate model. Finally,
when the presence of glomerulomegaly was considered as the
outcome variable, BMI (OR: 1.42; 95% CI: 1.14–1.76) showed
a significant association in the multivariate analysis.
Extremely obese patients. Univariate and multivariate
logistic regression models were performed exclusively in EO
patients (n¼ 95) to ascertain which clinical and biochemical
variables were associated with glomerular lesions (increased
mesangial matrix and/or mesangial cell proliferation and/or
podocyte hypertrophy) in this group (Table 4). A significant
univariate association was found among these glomerular
lesions and BMI, SAS, and obesity duration time. However,
Table 2 | Main histological renal lesions in 95 EO patients and 40 normal-weight controls
Histological renal lesions EO patients n=95 Normal-weight controls n=40 P-value
No. of glomerulia 34±32 (7–201) 75±37 (10–100) o0.001b
No. of patients with FSGS 5 (5.3%) 0 (0%) 0.321c
No. of glomeruli with FSGSa 1.6±0.5 (1–2) 0 0.003b
Percentage of glomeruli with FSGSa 6.3±3.4 (1.5–11) 0 0.015b
No. of patients with globally sclerotic glomeruli 50 (52.6%) 12 (30%) o0.05d
No. of globally sclerotic glomerulia 1.1±1.4 (0–7) 0.9±1.8; (0–8) NSb
Percentage of globally sclerosed glomerulia 4.7±7.3 (0–39) 1.4±3; (0–14) 0.007b
No. of patients with increased mesangial matrix 57 (60%) focal in 33; diffuse in 24 2 (5%) focal in 2 o0.001d
No. of patients with mesangial cell proliferation 19 (20%) focal in 11; diffuse in 8 0 (0 %) 0.005d
No. of patients with podocyte hypertrophy 38 (40%) focal 0 (0 %) o0.001d
No. of patients with any type of glomerular lesione 73 (77%) 2 (5%) o0.001d
No. of glomeruli measured by image analysis techniques
in every patienta
8.9±5.6 (3–30) 25±8; (8–30) o0.001b
No. of patients with glomerulomegaly 36 (38%) 1 (2.5%) o0.001d
Glomerular area (mm2)a 27 425±7473 19 086±4727 o0.001b
No. of patients with interstitial fibrosis and score 7 (7%) 1 (+) in 6 patients; 2 (+) in
1 patient
0 (0%) NSd
No. of patients with tubular atrophy and score 10 (11%) 1 (+) in 10 patients; 2 (+) in
1 patient
1(2.5%) 1 (+) in 1 patient NSd
No. of patients with arteriolar lesions and score 38 (40%) 1 (+) in 22 patients; 2 (+) in
16 patients
10 (25%) 1 (+) in 8 patients;
2 (+) in 2 patients
NSd
No. of patients with arterial lesions and score 27 (28%) 1 (+) in 20 patients; 2 (+) in
7 patients
8 (21%) 1 (+) in 8 patients NSd
EO, extremely obese; FSGS, focal and segmental glomerulosclerosis; n, number; NS, nonsignificant.
*Median values and interquartile ranges.
aMean±s.d. and range.
bStudent’s t-test.
cFisher’s exact test.
dPearson’s w2 test with continuity correction.
eNumber of patients with increased mesangial matrix and/or mesangial cell proliferation and/or podocyte hypertrophy.
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Figure 2 | Box plot of the median and interquartile range of
glomerular areas in extremely obese (EO) patients with or
without sleep apnea syndrome (SAS) and in controls. Non-SAS EO
vs SAS EO (P¼ 0.045); controls vs non-SAS EO (Po0.001); and controls
vs SAS EO (Po0.001).
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in the multivariate analysis, only BMI remained associated
with these glomerular lesions. When we stratified EO patients
according to the presence or absence of SAS, we did not find
any additional differences between both groups. When risk
factors for the presence of sclerosed glomeruli and glomerulo-
megaly were assessed, only age (OR: 1.93; 95% CI: 1.23–3.04)
and SAS (OR: 2.57; 95% CI: 1.08–6.10) (Table 5), respectively,
remained significant in the multivariate models.
DISCUSSION
This is the first study to show that extreme obesity is
associated with glomerular lesions (increased mesangial
matrix, mesangial cell proliferation, podocyte hypertrophy,
glomerulomegaly) in patients without overt clinical renal
disease. Additionally, FSGS was found in a significant
number of EO patients without overt renal manifestations.
In contrast, BMI (but not hypertension or hyperglycemia)
was associated with glomerular lesions in multivariate
analysis, whereas SAS was associated with glomerulomegaly.
Can obesity-related renal structural changes occur without
clinical renal involvement?
Our results demonstrate that glomerular lesions are asso-
ciated with extreme obesity. Therefore, obesity-related
glomerular structural changes can be seen in extreme obesity
without clinical renal manifestations. To our knowledge, this
is the first study to demonstrate that extreme obesity is
associated with glomerular lesions in patients with no
evidence of clinical renal disease. However, glomerular
lesions associated with early-stage obesity have been observed
in experimental animal studies.20,21 We believe that these
early renal lesions seen in EO patients could explain the
relationship between obesity and the risk of developing
chronic renal disease, as has been recently suggested in some
Table 3 | Risk factors associated with glomerular lesionsa (univariate and multivariate logistic regression models) in EO
patients and normal-weight controls (n=135)
Univariate Multivariateb
OR 95% CI P-value OR 95% CI P-value
Gender (male) 1.79 (0.90–3.57) 0.097 — —
Age (years)c 1.00 (0.73–1.37) 0.977 — —
BMI (kg m2)d 1.99 (1.59–2.50) o0.001 1.99 (1.59–2.50) o0.001
Systolic blood pressure (mm Hg)c 1.51 (1.15–1.98) 0.003 — —
Diastolic blood pressure (mm Hg)c 1.43 (1.05–1.96) 0.026 — —
Serum fasting glucose (mmol l1) 1.29 (0.96–1.74) 0.087 — —
Serum total cholesterol (mmol l1) 1.21 (0.84–1.74) 0.302 — —
Smoker 0.77 (0.35–1.68) 0.508 — —
BMI, body mass index; CI, confidence interval; EO, extremely obese; OR, odds ratio.
aGlomerular lesions were defined as the presence of increased mesangial matrix and/or mesangial cell proliferation and/or podocyte hypertrophy.
bStepwise method (forward selection).
cIncrease per 10 units.
dIncrease per 5 units.
Table 4 | Risk factors associated with glomerular lesionsa (univariate and multivariate logistic regression models) in EO
patients (n=95)
Univariate Multivariateb
OR 95% CI P-value OR 95% CI P-value
Gender (male) 1.18 (0.45–3.12) 0.740 — —
Age (years)c 1.14 (0.71–1.82) 0.599 — —
BMI (kg m2)d 1.70 (1.15–2.51) 0.009 1.70 (1.15–2.51) 0.009
Systolic blood pressure (mm Hg)c 1.22 (0.91–1.64) 0.192 — —
Diastolic blood pressure (mm Hg)c 1.40 (0.97–2.04) 0.074 — —
Serum fasting glucose (mmol l1) 0.99 (0.74–1.33) 0.976 — —
Serum total cholesterol (mmol l1) 1.10 (0.67–1.81) 0.696 — —
Serum triglycerides (mmol l1) 0.77 (0.34–1.74) 0.531 — —
Smoker 0.95 (0.36–2.46) 0.909 — —
Duration of obesity 1.01 (1.00–1.01) 0.030 — —
Sleep apnea syndrome 2.89 (1.02–8.23) 0.046 — —
BMI, body mass index; CI, confidence interval; EO, extremely obese; OR, odds ratio.
aGlomerular lesions were defined as the presence of increased mesangial matrix and/or mesangial cell proliferation and/or podocyte hypertrophy.
bStepwise method (forward selection).
cIncrease per 10 units.
dIncrease per 5 units.
Kidney International (2008) 73, 947–955 951
A Serra et al.: Renal injury in extreme obesity o r i g i n a l a r t i c l e
epidemiological studies.14–16 Mesangial matrix increase,
mesangial cell proliferation, podocyte hypertrophy, and
glomerulomegaly were the most common renal lesions
observed. Mesangial matrix increase and mesangial cell
proliferation have been reported in some obese humans with
overt renal disease9,12 but not in others.22 Podocyte
hypertrophy has been described in EO patients with
proteinuria9,12,22 but not in EO patients without overt renal
disease. Glomerulomegaly was seen in a one-third of our EO
patients and was the sole glomerular lesion in a small number
of cases. The relationship between extreme obesity and
glomerulomegaly was first suggested by Cohen.3 Subse-
quently, only a few studies have demonstrated glomerulo-
megaly using image analysis studies,5,10–12 mostly in patients
with FSGS and proteinuria.5,11,12,22 Some of these patients,
like ours, suffered from SAS.5,6 A recent study demonstrated
that obese live kidney donors have a larger glomerular area
than non-obese donors.23 We have no explanation for the fact
that only some of our EO patients showed glomerulomegaly
or other glomerular changes. This could be due to differences
in obesity-related renal injury stage, genetic predisposition,
or environmental conditioning. In contrast, all the glomeru-
lar lesions could be part of the same process.
Are FSGS or other renal lesions commonly seen in renal
biopsies of extremely obese patients without clinical renal
involvement?
Taking into account that our EO patients were devoid of
overt clinical renal manifestations, the proportion of cases
exhibiting FSGS (5.3%) was significant. No data are available
on similar groups of EO patients. Nevertheless, it is known
from retrospective studies that more than 70% of EO patients
with proteinuria revealed FSGS.2,3,8,9,12 Data on the general
population are also unavailable, although the annual
incidence of nephrosis (FSGS and minimal change disease)
is known to hover around 0.9 per 100 000 inhabitants.24 Our
EO patients with FSGS, similar to EO patients with FSGS and
proteinuria studied by others,12 revealed more severe
tubulointerstitial lesions and albuminuria than our EO
patients devoid of FSGS. This suggests that low-degree
albuminuria could be responsible for interstitial lesions, as
seen in experimental models of rats with proteinuria.25 In
analysis restricted to EO patients, FSGS was unassociated
with BMI, probably because of the relatively small variability
in BMI. A study including a larger BMI range (patients with
mild to moderate obesity) might reveal this or other
associations, but ethical considerations prevent its perfor-
mance.
Which variables were associated with glomerular lesions?
Body mass index and blood pressure were found to be
associated with glomerular lesions in EO patients and
normal-weight controls in the univariate model analysis.
However, in multivariate analysis, only BMI was associated
with glomerular lesions, which suggests that excess weight
per se is able to produce renal lesions regardless of other
causes of obesity-related kidney disease, such as arterial
hypertension or hyperglycemia.26,27 Therefore, early treat-
ment of obesity could prevent the development of chronic
renal failure, although it would be unable to thwart the
influence of other comorbid factors.
In our group of EO patients, only BMI was an
independent risk factor for developing glomerular lesions.
The lack of a relationship between arterial hypertension or
mild hyperglycemia and glomerular lesions in EO patients
with no evidence of clinical renal involvement would suggest
that the duration of these variables might not have been long
enough to produce renal lesions. The question arises whether
the renal lesions described in this study are non-progressive,
as clinical findings are either inconspicuous (absent or low-
degree albuminuria) or need the influence of other comorbid
factors to progress. Prospective clinical studies in this
biopsied group of EO patients are being carried out in our
hospital. Clinical follow-up and renal function assessment of
these subjects will help to determine the prognostic
significance of their kidney lesions.
Table 5 | Risk factors associated with glomerulomegaly (univariate and multivariate logistic regression models) in EO patients
(n=95)
Univariate Multivariatea
OR 95% CI P-value OR 95% CI P-value
Gender (male) 0.70 (0.30–1.66) 0.417 — —
Age (years)b 1.01 (0.97–1.05) 0.629 — —
BMI (kg m2)c 1.06 (1.00–1.11) 0.035 — —
Systolic blood pressure (mm Hg)b 0.99 (0.97–1.01) 0.504 — —
Diastolic blood pressure (mm Hg)b 1.01 (0.99 -1.01) 0.373 — —
Serum fasting glucose (mmol l1) 1.07 (0.82–1.40) 0.630 — —
Serum total cholesterol (mmol l1) 0.82 (0.54–1.27) 0.380 — —
Serum triglycerides (mmol l1) 1.07 (0.50–2.27) 0.861 — —
Smoker 0.52 (0.22–1.23) 0.135 — —
Duration of obesity (in months) 1.00 (1.00–1.01) 0.466 — —
Sleep apnea syndrome 2.69 (1.14–6.36) 0.024 2.57 (1.08–6.10) 0.032
BMI, body mass index; CI, confidence interval; EO, extremely obese; OR, odds ratio.
aStepwise method (forward selection).
bIncrease per 10 units.
cIncrease per 5 units.
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Sleep apnea syndrome was found to be associated with
glomerulomegaly in the multivariate analysis. Patients with
SAS show hypoxia, hypercapnia, and frequently, pulmonary
and systemic hypertension. These individuals have glomeru-
lar capillary hypertension secondary to increased intravas-
cular volume, hyperdynamic circulation, and renal vasodila-
tation.28 It is, therefore, possible that glomerulomegaly and
FSGS result from glomerular capillary hypertension acting in
conjunction with glomerular hyperfiltration favored by
enhanced renin–angiotensin system activity, increased sym-
pathetic nerve activity, and vascular resistance to leptin.5,6,29
In our series, glomerulomegaly (but not FSGS) was more
frequent in SAS patients than in non-SAS patients. We found
no association between glomerulomegaly and/or SAS with
glomerular hyperfiltration, which could be due to the fact
that our patients are in different stages of obesity-related
renal injury.
A question not addressed in this study was whether
extreme obesity treatment either with bariatric surgery,
which results in drastic weight loss, or angiotensin-convert-
ing enzyme inhibitors and/or statins could reverse renal
lesions, as observed in experimental studies of obese Zucker
rats.30 We know from studies of ours and others that weight
loss after bariatric surgery spectacularly improves clinical
hypertension31–34 and biochemical indicators (hyperglyce-
mia, hypercholesterolemia, proteinuria, microalbuminur-
ia).33–35 However, subsequent histological studies were not
performed in EO patients on ethical grounds.
To our knowledge, no similar studies have focused on the
clinicopathological correlations and risk factors in EO
patients without overt renal disease. A limitation of our
study was that for ethical reasons, we had no access to
histological studies of overweight subjects and mildly or
moderately obese patients. Consequently, our data are only
applicable to EO patients and normal-weight adults. How-
ever, this study does suggest that the risk of developing renal
disease increases with the severity of obesity.
In conclusion, our findings suggest that EO patients
without clinical renal manifestations show obesity-related
renal structural changes that mainly involve the glomerular
compartment. We also found that the risk factors for
developing glomerular lesions in these patients were
weight-related. Hypertension and hyperglycemia did not
reach statistical significance as independent risk factors for
glomerular lesions.
MATERIALS AND METHODS
The 95 EO patients studied stemmed from the 130 EO patients with
no known clinical history of renal disease (renal failure, overt
proteinuria, or hematuria) who consecutively underwent open
bariatric surgery at our institution between December 2001 and
November 2005 and were invited to participate in this study
(complete clinical and biochemical evaluation before surgery, renal
biopsy at surgery, and clinical and biochemical long-term follow-
up). Of the 130 cases, 5 patients declined to participate, renal biopsy
was not performed in 14 patients for technical reasons, and 16
patients had insufficient renal tissue available for analysis. The
remaining 95 patients fulfilled the criteria and were included in the
study. These 95 EO patients are also included in an ongoing
prospective clinical and biochemical long-term follow-up study. All
patients met the criteria for surgery according to the National
Institutes of Health and Spanish Consensus.36,37 The surgical
technique performed was gastric bypass according to either the
method described by Fobi et al.38 or that of Salmon.39 Only nine EO
patients surgically intervened during the study period were not
included in the project, due to their overt renal manifestations (mild
chronic renal failure in four and proteinuria in five).
No patient was on insulin, lipid-lowering drugs, nonsteroidal
anti-inflammatory agents, or oral antidiabetic treatment. Twenty-
eight patients were being treated for hypertension (7 with
angiotensin-converting enzyme inhibitors, 3 with angiotensin II
receptor blockers, 4 with diuretics, 2 with b blockers, and 12 with
angiotensin-converting enzyme inhibitors and/or angiotensin II
receptor blockers in combination with other drugs). Medications
were withdrawn 8 days before the analyses. Fifty-one patients were
included in another recently published clinical study.34
Clinical and biochemical studies were performed in 25 normal-
weight subjects with benign or malignant focal renal tumors before
nephrectomy and in 15 stable normal-weight kidney donors before
the diagnosis of brain death; all these 40 individuals served as
controls. Preoperative blood samples were drawn between 08:00 and
09:00 h after an overnight fast in specialized rooms prepared for
controlled metabolic studies. Urine samples were collected in the
previous 24-h period. Serum glucose, total cholesterol, triglycerides,
and creatinine and urine creatinine were measured with a routine
clinical chemistry laboratory analyzer. Creatinine clearance was
calculated as 24-h urine (ml) urinary creatinine con-
centration 1000/plasma creatinine concentration 1440 min.
Twenty-four hour proteinuria was measured by a spectrophoto-
metric method and 24-h albuminuria by nephelometry.
Renal biopsies in EO patients were performed during bariatric
surgery with the aid of a Gallini Medical Devices needle
(14 G 11 cm). Tissue samples were routinely processed in EO
patients for histology, direct immunofluorescence, and electron
microscopy according to standard procedures and image analysis
techniques. In the control group, samples were only processed for
light microscopy and image analysis techniques. Renal biopsies were
reviewed by two blinded independent pathologists. FSGS was
defined as focal and segmental consolidation of the glomerular tuft
by increased extracellular matrix, with obliteration of capillary
lumina. Globally sclerosed glomeruli were considered to be present
when the entire glomerular tuft was sclerosed. Mesangial matrix
increase was defined as mesangial sclerosis causing diffuse widening
of the mesangium. Mesangial cell proliferation was the presence of
more than three mesangial cells surrounded by mesangial matrix in
an intact glomerular segment in 3-mm-thick sections. Podocyte
hypertrophy was defined as podocyte enlargement with large nuclei
and prominent nucleoli, with or without intracytoplasmic protein
resorption droplets.40 Any of these changes was considered to be
diffusely present when 450% of glomeruli were involved and
focally present when o50% of glomeruli were involved. In cases
with focal involvement, the percentage of glomeruli showing the
change was always 410. Interstitial fibrosis and tubular atrophy
were semiquantitatively scored according to the percentage of
involved cortical surface as follows: 0o15%, 1þ ¼ 15–25%,
2þ ¼ 26–50%, 3þ ¼450%. Arteriolosclerosis and arteriosclerosis
were scored as follows: 0¼ absent, 1þ ¼mild, 2þ ¼moderate,
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3þ ¼ severe. Immunofluorescence was carried out by incubating
cryostat sections with polyclonal FITC-conjugated antibodies to
IgG, IgM, IgA, C3, C1q, C4, kappa, lambda, and fibrinogen (Dako
Corporation, Copenhagen, Denmark). Every section contained 3–5
glomeruli and a semiquantitative assessment of staining intensity
was given as negative (0), mild (1þ ), moderate (2þ ), or strong
(3þ ). Glomerular area image analysis was performed on periodic
acid-Schiff-stained sections in a blinded fashion by a single
investigator in 93 patients and 40 controls. Only glomeruli
containing visible vascular pole were measured. Glomerular images
were digitized using a Hamamatsu C5810 color camera attached to a
Zeiss Axioskop2 fluorescence light microscope. After digitalization,
glomerular tufts were traced and the areas were calculated using
image analysis software (Openlab; Improvision Ltd., Coventry, UK).
The mean of each area measured was calculated.
For logistic regression analysis, ‘presence of glomerular lesions’
was defined as the occurrence of increased mesangial matrix and/or
mesangial cell proliferation and/or podocyte hypertrophy. ‘Presence
of sclerosed glomeruli’ meant that the percentage of sclerosed
glomeruli was above 1.5 (mean of the percentage of sclerosed
glomeruli in the control group), whereas ‘presence of glomerulo-
megaly’ implied that the glomerular area was above the glomerular
area mean in the control group plus two standard deviations.
Body mass index was calculated as weight (kg)/height (m)2.
Blood pressure was measured using a standard mercury sphygmo-
manometer of appropriate cuff size. High casual systolic and
diastolic blood pressures were defined as X140 and X90 mm Hg,
respectively, in two different measurements. Arterial hypertension
was considered to be present when the patient showed either high
casual systolic or diastolic readings. The presence of SAS was
considered positive when the apnea–hypopnea index/sleep hour was
above 5.41 Diabetes mellitus was defined as fasting serum glucose
levels X7.0 mmol l1 in two determinations and impaired fasting
glucose as fasting serum glucose levels X5.6 and o7.0 mmol l1.42
Hypercholesterolemia and hypertriglyceridemia were defined as
serum total cholesterol 45.17 mmol l1 and serum triglycerides
41.71 mmol l1.43,44 Glomerular filtration rate was estimated using
creatinine clearance measured on a 24-h urine sample, without
correction for body surface area, which would considerably under-
estimate the real glomerular filtration value.45 Glomerular hyperfil-
tration was considered to be present when creatinine clearance was
4140 ml min1.46,47 Microalbuminuria was defined as albumin
levels in 24-h urine between 30 and 300 mg and proteinuria as
albuminuria 4300 mg per 24 h or proteinuria levels in 24-h urine
40.30 g. We considered the duration of obesity (in months) as the
time elapsed between the onset of ‘extreme’ obesity and the
performance of the kidney biopsy.
Ethics
Patients were selected for surgery according to the criteria of our
hospital’s Obesity Unit. When possible, renal biopsies were obtained
performing a maximum of two punctures in every patient. The
project was approved by our hospital’s Institutional Review Board
(protocol no. EO-00-010). All patients gave their written informed
consent to participate in the study.
Statistical analysis
For the descriptive analysis, qualitative and quantitative characteris-
tics were summarized using percentages and mean values plus the
standard error (or median values and interquartile ranges),
respectively. Comparisons of the main characteristics between EO
patients and controls, as well as associations between clinical,
biochemical, and pathological data, were made using Pearson’s w2 or
Fisher’s exact test, and Student’s t-test or Mann–Whitney U-test, as
appropriate. To assess the association between clinical and
biochemical variables and glomerular lesions, logistic regression
models were performed using stepwise forward variable selection
based on the likelihood ratio test. OR and their 95% CIs were
computed. The model-building strategy was to consider all
significant univariate associations at level 0.25 as potential risk
factors for the adjusted model.
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